Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.

Autor: Rabdano SO; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia. Electronic address: sevastyan@rabdano.ru., Ruzanova EA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Vertyachikh AE; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Teplykh VA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Emelyanova AB; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Rudakov GO; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Arakelov SA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Pletyukhina IV; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Saveliev NS; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Lukovenko AA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Fakhretdinova LN; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Safi AS; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Zhirenkina EN; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Polyakova IN; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Belozerova NS; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Klykov VV; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Savelieva AP; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Ekimov AA; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Pokachalov KV; Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia., Merkulov VA; I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; Centre for Evaluation and Control of Finished Pharmaceutical Products, Federal State Budgetary Institution 'Scientific Centre for Expert Evaluation of Medicinal Products' of the Ministry of Health of the Russian Federation, Moscow, Russia., Yudin SM; Centre for Strategic Planning of FMBA of Russia Federal State Budgetary Institution 'Centre for Strategic Planning and Management of Biomedical Health Risks' of the Federal Medical Biological Agency, Moscow, Russia., Kruchko DS; Federal Medical-Biological Agency of Russia, Moscow, Russia., Berzin IA; Federal Medical-Biological Agency of Russia, Moscow, Russia., Skvortsova VI; Federal Medical-Biological Agency of Russia, Moscow, Russia.

Publikováno v: The Journal of infection [J Infect] 2024 Nov; Vol. 89 (5), pp. 106288. Date of Electronic Publication: 2024 Sep 26.

[A possible variant of a false diagnosis of infection with the human immunodeficiency virus].

Autor: Kalikanov SA, Chabanenko AI, Reznikov IuP, Arakelov SA, Stakhanova VM

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 1990; Vol. 62 (1), pp. 97-9.

[Use of highly sensitive methods of detecting hepatitis B virus markers for studying epidemic foci of hepatitis B].

Autor: Mukomolov SL, Arakelov SA, Shliakhtenko LI, Anan'ev VA, Nechaev VV

Publikováno v: Voprosy virusologii [Vopr Virusol] 1985 Jan-Feb; Vol. 30 (1), pp. 71-5.

[Immunoenzyme method for demonstrating the antigen and antibodies to the human immunodeficiency virus and its use for the serological examination of different population groups].

Autor: Zhdanov VM, Karamov EV, Arakelov SA, Rudneva IA, Ketiladze ES

Publikováno v: Voprosy virusologii [Vopr Virusol] 1988 May-Jun; Vol. 33 (3), pp. 294-8.